行情

CRBP

CRBP

Corbus制药控股
NASDAQ

实时行情|Nasdaq Last Sale

0.2143
+0.0043
+2.05%
盘后: 0.2362 +0.0219 +10.22% 19:30 05/13 EDT
开盘
0.2300
昨收
0.2100
最高
0.2359
最低
0.2099
成交量
506.47万
成交额
0
52周最高
2.290
52周最低
0.2080
市值
2,684.23万
市盈率(TTM)
-0.5571
分时
5日
1月
3月
1年
5年
Corbus Presents Latest Preclinical Data For CRB-601 At The New York Academy Of Sciences Frontiers In Cancer Immunotherapy Conference
CRB-601 is a highly potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment Additional non-clinical data
Benzinga · 5天前
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that new preclinical data for CRB-601 are being presented today in an oral presentation at the New York Academy of Sciences (NYAS) Frontiers ...
PR Newswire · 5天前
Corbus Pharmaceuticals: Q1 Earnings Insights
  Corbus Pharmaceuticals (NASDAQ:CRBP) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 5天前
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5天前
Corbus Pharmaceuticals GAAP EPS of -$0.08 beats by $0.01
Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q1 GAAP EPS of -$0.08 beats by $0.01. As of March 31, 2022, the company has $86.8 million of cash and investments on hand which
Seekingalpha · 6天前
BRIEF-Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results
reuters.com · 6天前
Marijuana Stock Movers For April 28, 2022
GAINERS: GreenTree Hospitality Gr (NYSE:GHG) shares closed up 11.87% at $4.50
Benzinga · 04/28 21:16
Cannabis Stock Gainers And Losers From April 25, 2022
GAINERS: SOL Global Investments (OTC:SOLCF) shares closed up 11.39% at $0.92
Benzinga · 04/25 22:23
更多
暂无数据
了解CRBP最新的财务预测,通过CRBP每股收益,每股净资产,每股现金流等数据分析Corbus制药控股近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
33.33%买入
66.67%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CRBP价格均价为1.980,最高价位3.000,最低价为0.9600。
最高3.000
均价1.980
最低0.9600
现价0.2143
EPS
实际EPS
预期EPS
-0.12-0.09-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 161
机构持股: 5,104.24万
持股比例: 40.75%
总股本: 1.25亿
类型机构数股数
增持
27
189.51万
建仓
14
58.43万
减持
19
185.33万
平仓
18
78.61万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+4.50%
制药与医学研究
+1.39%
高管信息
Non-Executive Chairman/Independent Director
Alan Holmer
Chief Executive Officer/Director
Yuval Cohen
Chief Financial Officer/IR Contact Officer
Sean Moran
Chief Operating Officer
Craig Millian
Chief Scientific Officer
Rachael Brake
Independent Director
Avery Catlin
Independent Director
Rachelle Jacques
Independent Director
John Jenkins
Independent Director
Peter Salzmann
暂无数据
暂无数据
CRBP 简况
Corbus Pharmaceuticals Holdings Inc是一家三期临床阶段制药公司,专注于针对自身免疫、纤维化和癌症领域的内源性大麻素系统的新型疗法的开发和商业化。该公司开发了各种各样的候选药物,包括小分子和生物制剂。该公司的主要候选产品Lenabasum是一种新型合成口服大麻素受体2型(CB2)激动剂,旨在解决慢性炎症、限制纤维化和支持组织修复。Lenabasum正在临床开发,用于治疗自身免疫性疾病。该公司正在评估lenabasum,并且正在皮肌炎的III期研究中,以及系统性红斑狼疮(SLE)的II期研究中。该公司设计大麻素受体1型(CB1)反向激动剂以使代谢异常正常化或限制炎症和纤维化。

微牛提供Corbus Pharmaceuticals Holdings Inc(NASDAQ-CRBP)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CRBP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CRBP股票基本功能。